|
09 May 2022 |
Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors
|
|
06 May 2022 |
Abelacimab: First Factor XI Inhibitor to Enroll Patients in a Phase 3 Clinical Trial
|
|
05 May 2022 |
Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines
|
|
05 May 2022 |
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder
|
|
05 May 2022 |
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
|
|
05 May 2022 |
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
|
|
05 May 2022 |
Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
|
|
04 May 2022 |
Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma
|
|
04 May 2022 |
Imfinzi plus chemotherapy granted Priority Review in the US for patients with locally advanced or metastatic biliary tract cancer based on TOPAZ-1 Phase III trial
|
|
04 May 2022 |
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
|
|
02 May 2022 |
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
|
|
02 May 2022 |
Ingenia Therapeutics & Mosaic Biosciences Present Preclinical Data on the Variants of the Bispecific Antibody IGT-427 for the Treatment of Degenerative Retinal Diseases
|
|
02 May 2022 |
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
|
|
02 May 2022 |
Junshi Biosciences and Coherus Receive Complete Response Letter from U.S. FDA for Toripalimab BLA
|
|
02 May 2022 |
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
|
|
01 May 2022 |
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
|
|
01 May 2022 |
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
|
|
01 May 2022 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer
|
|
01 May 2022 |
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1)
|
|
28 Apr 2022 |
AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
|
|
28 Apr 2022 |
Ultomiris approved in the US for adults with generalised myasthenia gravis
|
|
28 Apr 2022 |
Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study
|
|
26 Apr 2022 |
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
|
|
26 Apr 2022 |
Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi
|
|
21 Apr 2022 |
Immune-Onc Therapeutics Announces the Selection of Clinical Development Candidate IO-106, a First-in-Class Myeloid and Stromal Checkpoint Inhibitor Targeting LAIR1
|
